A citation-based method for searching scientific literature

Yitian Zhou, Volker M Lauschke. J Med Genet 2018
Times Cited: 18







List of co-cited articles
195 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Integrating rare genetic variants into pharmacogenetic drug response predictions.
Magnus Ingelman-Sundberg, Souren Mkrtchian, Yitian Zhou, Volker M Lauschke. Hum Genomics 2018
105
66

Genetic variation in the human cytochrome P450 supergene family.
Kohei Fujikura, Magnus Ingelman-Sundberg, Volker M Lauschke. Pharmacogenet Genomics 2015
97
61


Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network.
W S Bush, D R Crosslin, A Owusu-Obeng, J Wallace, B Almoguera, M A Basford, S J Bielinski, D S Carrell, J J Connolly, D Crawford,[...]. Clin Pharmacol Ther 2016
114
50

Analysis of protein-coding genetic variation in 60,706 humans.
Monkol Lek, Konrad J Karczewski, Eric V Minikel, Kaitlin E Samocha, Eric Banks, Timothy Fennell, Anne H O'Donnell-Luria, James S Ware, Andrew J Hill, Beryl B Cummings,[...]. Nature 2016
44

Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics.
María Santos, Mikko Niemi, Masahiro Hiratsuka, Masaki Kumondai, Magnus Ingelman-Sundberg, Volker M Lauschke, Cristina Rodríguez-Antona. Genet Med 2018
52
38

Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset.
Adam S Gordon, Holly K Tabor, Andrew D Johnson, Beverly M Snively, Themistocles L Assimes, Paul L Auer, John P A Ioannidis, Ulrike Peters, Jennifer G Robinson, Lara E Sucheston,[...]. Hum Mol Genet 2014
64
38

Precision Medicine and Rare Genetic Variants.
Volker M Lauschke, Magnus Ingelman-Sundberg. Trends Pharmacol Sci 2016
43
38

An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Yitian Zhou, Souren Mkrtchian, Masaki Kumondai, Masahiro Hiratsuka, Volker M Lauschke. Pharmacogenomics J 2019
67
38

The global spectrum of protein-coding pharmacogenomic diversity.
G E B Wright, B Carleton, M R Hayden, C J D Ross. Pharmacogenomics J 2018
51
38

Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments.
Volker M Lauschke, Lili Milani, Magnus Ingelman-Sundberg. AAPS J 2017
78
33

Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data.
Yitian Zhou, Kohei Fujikura, Souren Mkrtchian, Volker M Lauschke. Front Pharmacol 2018
42
33

How to Consider Rare Genetic Variants in Personalized Drug Therapy.
Volker M Lauschke, Magnus Ingelman-Sundberg. Clin Pharmacol Ther 2018
28
33


Predicting the functional impact of protein mutations: application to cancer genomics.
Boris Reva, Yevgeniy Antipin, Chris Sander. Nucleic Acids Res 2011
27

Heritability of metoprolol and torsemide pharmacokinetics.
J Matthaei, J Brockmöller, M V Tzvetkov, D Sehrt, C Sachse-Seeboth, J B Hjelmborg, S Möller, U Halekoh, U Hofmann, M Schwab,[...]. Clin Pharmacol Ther 2015
41
22

Predicting the functional effect of amino acid substitutions and indels.
Yongwook Choi, Gregory E Sims, Sean Murphy, Jason R Miller, Agnes P Chan. PLoS One 2012
22

Identifying Mendelian disease genes with the variant effect scoring tool.
Hannah Carter, Christopher Douville, Peter D Stenson, David N Cooper, Rachel Karchin. BMC Genomics 2013
258
22

Requirements for comprehensive pharmacogenetic genotyping platforms.
Volker M Lauschke, Magnus Ingelman-Sundberg. Pharmacogenomics 2016
33
22

A method and server for predicting damaging missense mutations.
Ivan A Adzhubei, Steffen Schmidt, Leonid Peshkin, Vasily E Ramensky, Anna Gerasimova, Peer Bork, Alexey S Kondrashov, Shamil R Sunyaev. Nat Methods 2010
22

Predicting deleterious amino acid substitutions.
P C Ng, S Henikoff. Genome Res 2001
22

A global reference for human genetic variation.
Adam Auton, Lisa D Brooks, Richard M Durbin, Erik P Garrison, Hyun Min Kang, Jan O Korbel, Jonathan L Marchini, Shane McCarthy, Gil A McVean, Gonçalo R Abecasis. Nature 2015
22

Performance evaluation of pathogenicity-computation methods for missense variants.
Jinchen Li, Tingting Zhao, Yi Zhang, Kun Zhang, Leisheng Shi, Yun Chen, Xingxing Wang, Zhongsheng Sun. Nucleic Acids Res 2018
117
22


High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme.
M Apellániz-Ruiz, L Inglada-Pérez, M E G Naranjo, L Sánchez, V Mancikova, M Currás-Freixes, A A de Cubas, I Comino-Méndez, S Triki, A Rebai,[...]. Pharmacogenomics J 2015
40
22

African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development.
Iris Rajman, Laura Knapp, Thomas Morgan, Collen Masimirembwa. EBioMedicine 2017
59
22



The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity.
Volker M Lauschke, Magnus Ingelman-Sundberg. Int J Mol Sci 2016
51
16

The Phyre2 web portal for protein modeling, prediction and analysis.
Lawrence A Kelley, Stefans Mezulis, Christopher M Yates, Mark N Wass, Michael J E Sternberg. Nat Protoc 2015
16


mrSNP: software to detect SNP effects on microRNA binding.
Mehmet Deveci, Umit V Catalyürek, Amanda Ewart Toland. BMC Bioinformatics 2014
42
16

An integrated map of genetic variation from 1,092 human genomes.
Goncalo R Abecasis, Adam Auton, Lisa D Brooks, Mark A DePristo, Richard M Durbin, Robert E Handsaker, Hyun Min Kang, Gabor T Marth, Gil A McVean. Nature 2012
16

Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.
Marin M Jukić, Tore Haslemo, Espen Molden, Magnus Ingelman-Sundberg. Am J Psychiatry 2018
87
16


A general framework for estimating the relative pathogenicity of human genetic variants.
Martin Kircher, Daniela M Witten, Preti Jain, Brian J O'Roak, Gregory M Cooper, Jay Shendure. Nat Genet 2014
16

Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol.
Suzette J Bielinski, Janet E Olson, Jyotishman Pathak, Richard M Weinshilboum, Liewei Wang, Kelly J Lyke, Euijung Ryu, Paul V Targonski, Michael D Van Norstrand, Matthew A Hathcock,[...]. Mayo Clin Proc 2014
201
16

MicroSNiPer: a web tool for prediction of SNP effects on putative microRNA targets.
Maxim Barenboim, Brad J Zoltick, Yongjian Guo, Daniel R Weinberger. Hum Mutat 2010
116
16

ImiRP: a computational approach to microRNA target site mutation.
Bridget C Ryan, Torben S Werner, Perry L Howard, Robert L Chow. BMC Bioinformatics 2016
13
23

HLA-B*5701 screening for hypersensitivity to abacavir.
Simon Mallal, Elizabeth Phillips, Giampiero Carosi, Jean-Michel Molina, Cassy Workman, Janez Tomazic, Eva Jägel-Guedes, Sorin Rugina, Oleg Kozyrev, Juan Flores Cid,[...]. N Engl J Med 2008
16

Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication.
Xiaojing Tang, Shuqing Chen. Curr Drug Metab 2015
43
16

Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Mary V Relling, Matthias Schwab, Michelle Whirl-Carrillo, Guilherme Suarez-Kurtz, Ching-Hon Pui, Charles M Stein, Ann M Moyer, William E Evans, Teri E Klein, Federico Guillermo Antillon-Klussmann,[...]. Clin Pharmacol Ther 2019
279
16

Finding the missing heritability of complex diseases.
Teri A Manolio, Francis S Collins, Nancy J Cox, David B Goldstein, Lucia A Hindorff, David J Hunter, Mark I McCarthy, Erin M Ramos, Lon R Cardon, Aravinda Chakravarti,[...]. Nature 2009
16

PGRNseq: a targeted capture sequencing panel for pharmacogenetic research and implementation.
Adam S Gordon, Robert S Fulton, Xiang Qin, Elaine R Mardis, Deborah A Nickerson, Steve Scherer. Pharmacogenet Genomics 2016
78
16

Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor.
Thomas Jacob Urban, Paola Nicoletti, Naga Chalasani, José Serrano, Andrew Stolz, Ann K Daly, Guruprasad P Aithal, John Dillon, Victor Navarro, Joseph Odin,[...]. J Hepatol 2017
74
16

Medical genetics: a marker for Stevens-Johnson syndrome.
Wen-Hung Chung, Shuen-Iu Hung, Hong-Shang Hong, Mo-Song Hsih, Li-Cheng Yang, Hsin-Chun Ho, Jer-Yuarn Wu, Yuan-Tsong Chen. Nature 2004
16

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.
Shuen-Iu Hung, Wen-Hung Chung, Lieh-Bang Liou, Chen-Chung Chu, Marie Lin, Hsien-Ping Huang, Yen-Ling Lin, Joung-Liang Lan, Li-Cheng Yang, Hong-Shang Hong,[...]. Proc Natl Acad Sci U S A 2005
839
16

A randomized trial of genotype-guided dosing of warfarin.
Munir Pirmohamed, Girvan Burnside, Niclas Eriksson, Andrea L Jorgensen, Cheng Hock Toh, Toby Nicholson, Patrick Kesteven, Christina Christersson, Bengt Wahlström, Christina Stafberg,[...]. N Engl J Med 2013
573
16

Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions.
Sulev Reisberg, Kristi Krebs, Maarja Lepamets, Mart Kals, Reedik Mägi, Kristjan Metsalu, Volker M Lauschke, Jaak Vilo, Lili Milani. Genet Med 2019
48
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.